Trump Advances Psychedelic Drug Policy With New Executive Order
President Donald Trump is moving forward with a major shift in U.S. drug policy, but the science and risks are still unsettled.
According to Reuters and CBS News, Trump signed an executive order to fast-track research and potential approval of psychedelic drugs like ibogaine, LSD, and psilocybin for mental health treatment. The policy includes $50 million in federal funding and directs the FDA to accelerate clinical trials.
Supporters say the move could transform care for conditions like PTSD, depression, and addiction, especially for veterans. But critics warn the evidence remains limited, and safety concerns persist after past FDA setbacks involving similar therapies.
Subscribe free for daily political analysis they won’t broadcast. Join 110K+ readers →
The order does not immediately legalize these drugs, which remain Schedule I substances, though officials signaled reclassification could follow successful trials.
The action builds on Trump’s earlier push to ease marijuana restrictions, suggesting a broader federal shift on controlled substances.
What happens next depends on FDA reviews and whether the science holds up.
Download a FREE Pocket Constitution NOW →
